CA1103314A - Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline - Google Patents

Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline

Info

Publication number
CA1103314A
CA1103314A CA297,510A CA297510A CA1103314A CA 1103314 A CA1103314 A CA 1103314A CA 297510 A CA297510 A CA 297510A CA 1103314 A CA1103314 A CA 1103314A
Authority
CA
Canada
Prior art keywords
insulin
blood glucose
rate
infusion
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA297,510A
Other languages
English (en)
Inventor
Ryuzo Kawamori
Hiroshi Abe
Shozo Ohara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nikkiso Co Ltd
Original Assignee
Nikkiso Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikkiso Co Ltd filed Critical Nikkiso Co Ltd
Priority to CA297,510A priority Critical patent/CA1103314A/fr
Application granted granted Critical
Publication of CA1103314A publication Critical patent/CA1103314A/fr
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28—Electrolytic cell components
    • G01N27/30—Electrodes, e.g. test electrodes; Half-cells
    • G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
    • G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CA297,510A 1978-02-21 1978-02-21 Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline Expired CA1103314A (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA297,510A CA1103314A (fr) 1978-02-21 1978-02-21 Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA297,510A CA1103314A (fr) 1978-02-21 1978-02-21 Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline

Publications (1)

Publication Number Publication Date
CA1103314A true CA1103314A (fr) 1981-06-16

Family

ID=4110840

Family Applications (1)

Application Number Title Priority Date Filing Date
CA297,510A Expired CA1103314A (fr) 1978-02-21 1978-02-21 Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline

Country Status (1)

Country Link
CA (1) CA1103314A (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536249A (en) * 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5820602A (en) * 1995-09-08 1998-10-13 Visionary Medical Products, Inc. Pen-type injector drive mechanism
US6613011B2 (en) 2001-04-13 2003-09-02 Penjet Corporation Gas-pressured engine with valve

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536249A (en) * 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5593390A (en) * 1994-03-09 1997-01-14 Visionary Medical Products, Inc. Medication delivery device with a microprocessor and characteristic monitor
US5728074A (en) * 1994-03-09 1998-03-17 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5925021A (en) * 1994-03-09 1999-07-20 Visionary Medical Products, Inc. Medication delivery device with a microprocessor and characteristic monitor
US5820602A (en) * 1995-09-08 1998-10-13 Visionary Medical Products, Inc. Pen-type injector drive mechanism
US6613011B2 (en) 2001-04-13 2003-09-02 Penjet Corporation Gas-pressured engine with valve

Similar Documents

Publication Publication Date Title
Shichiri et al. Normalization of the paradoxic secretion of glucagon in diabetics who were controlled by the artificial beta cell
Mirouze et al. Evaluation of exogenous insulin homoeostasis by the artificial pancreas in insulin-dependent diabetes
Kawamori et al. Importance of insulin secretion based on the rate of change in blood glucose concentration in glucose tolerance, assessed by the artificial beta cell
CA1040271A (fr) Cellule beta artificielle
Dimitriadis et al. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus
Sigal et al. Hyperinsulinemia prevents prolonged hyperglycemia after intense exercise in insulin-dependent diabetic subjects
Raskin et al. Changes in glucagon levels after four to five weeks of glucoregulation by portable insulin infusion pumps
SACKS et al. Similar responsiveness of diabetic ketoacidosis to low-dose insulin by intramuscular injection and albumin-free infusion
GB1574267A (en) Apparatus for controlling a quantity of insulin infusion
Kawamori et al. Mechanism of exercise-induced hypoglycemia in depancreatized dogs maintained on long-acting insulin.
Tsujimoto et al. Rapid onset of glycogen storage hepatomegaly in a type-2 diabetic patient after a massive dose of long-acting insulin and large doses of glucose
Madsbad et al. The transient effect of strict glycaemic control on B cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients
Ferrannini et al. Pattern of insulin delivery after intravenous glucose injection in man and its relation to plasma glucose disappearance.
Lauritzen et al. Importance of insulin absorption, subcutaneous blood flow, and residual beta‐cell function in insulin therapy
Martin et al. Continuous low-dose infusion of insulin in the treatment of diabetic ketoacidosis in children
Kanarek et al. Continuous infusion of insulin in hyperglycemic low‐birth weight infants receiving parenteral nutrition with and without lipid emulsion
Skor et al. Relative roles of insulin clearance and insulin sensitivity in the prebreakfast increase in insulin requirements in insulin-dependent diabetic patients
Gauthier et al. Importance of glucagon in regulatory rather than emergency responses to hypoglycemia
Gormley et al. One month's insulin treatment of type II diabetes: the early and medium-term effects following insulin withdrawal
CA1103314A (fr) Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline
Sherwin et al. Treatment of juvenile-onset diabetes by subcutaneous infusion of insulin with a portable pump
Stevenson et al. Matched glucose responses to insulin administered subcutaneously and intravenously: Evidence for subcutaneous inactivation of insulin
Wasada et al. Evidence for a role of free fatty acids in the regulation of somatostatin secretion in normal and alloxan diabetic dogs
Jeng et al. How does glibenclamide lower plasma glucose concentration in patients with type 2 diabetes?
Bottermann et al. Insulin concentrations and time-action profiles of three different intermediate-acting insulin preparations in nondiabetic volunteers under glucose-controlled glucose infusion technique

Legal Events

Date Code Title Description
MKEX Expiry